NFE2L2 and neuroblastoma: In respect to MYCN, a study showed that the aggressive neuroblastoma cell line HTLA-230 bearing MYCN amplification was slightly sensitive to bortezomib (BTZ), a selective inhibitor of the proteasome, due to NRF2 activation and subsequent upregulation of the antioxidant heme oxygenase-1 (HO-1).